

Clinical Policy: Plecanatide (Trulance)

Reference Number: CP.PMN.87

Effective Date: 02.01.17

Last Review Date: 02.25

Line of Business: Commercial, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Plecanatide (Trulance[®]) is a guanylate cyclase-C agonist.

FDA Approved Indication(s)

Trulance is indicated in adults for the treatment of:

- Chronic idiopathic constipation (CIC)
- Irritable bowel syndrome with constipation (IBS-C)

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Trulance is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Chronic Idiopathic Constipation (must meet all):

1. Diagnosis of CIC;
2. Age \geq 18 years;
3. Failure of one bulk forming laxative (e.g., psyllium (Metamucil[®]), methylcellulose (Citrucel[®]), calcium polycarbophil (FiberCon[®])), unless clinically significant adverse effects are experienced or all are contraindicated;
4. Failure of one stimulant laxative (e.g., bisacodyl, senna), unless clinically significant adverse effects are experienced or all are contraindicated;
5. Failure of polyethylene glycol (MiraLax[®]) at up to maximally indicated doses, unless contraindicated or clinically significant adverse effects are experienced;
6. Failure of generic lubiprostone, unless contraindicated or clinically significant adverse effects are experienced;
7. Failure of Linzess[®], unless contraindicated or clinically significant adverse effects are experienced;
8. Dose does not exceed 3 mg (1 tablet) per day.

Approval duration: 12 months

B. Irritable Bowel Syndrome with Constipation (must meet all):

1. Diagnosis of IBS-C;
2. Age \geq 18 years;

3. Failure of one bulk-forming laxative (e.g. psyllium (Metamucil), methylcellulose (Citrucel), calcium polycarbophil (FiberCon)), unless clinically significant adverse effects are experienced or all are contraindicated;
4. Failure of generic lubiprostone, unless contraindicated or clinically significant adverse effects are experienced;
5. Failure of Linzess, unless contraindicated or clinically significant adverse effects are experienced;
6. Dose does not exceed 3 mg (1 tablet) per day.

Approval duration: 12 months

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Member meets one of the following (a or b):
 - a. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
 - b. Member is currently receiving medication and is enrolled in a state and product with continuity of care regulations (*refer to state specific addendums for CC.PHARM.03A and CC.PHARM.03B*);
2. Member is responding positively to therapy;
3. If request is for a dose increase, new dose does not exceed 3 mg (1 tablet) per day.

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.255 for Medicaid; or

- b. For drugs NOT on the formulary (commercial, health insurance marketplace) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial and CP.PMN.16 for Medicaid; or
- 2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies – CP.CPA.09 for commercial and CP.PMN.53 for Medicaid, or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CIC: chronic idiopathic constipation

FDA: Food and Drug Administration

IBS-C: irritable bowel syndrome with constipation

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
psyllium (Metamucil [®])	1 rounded teaspoonful, tablespoonful, or premeasured packet in 240 mL of fluid PO, 1 to 3 times per day (2.4 g of soluble dietary fiber per dose)	7.2 g (as soluble dietary fiber)/day
calcium polycarbophil (FiberCon [®])	1,000 mg 1 to 4 times per day or as needed	6,000 mg/day
methylcellulose (Citrucel [®])	Caplet: 2 caplets (total 1 g methylcellulose) PO with at least 240 ml (8 oz) of liquid, up to 6 times per day as needed Powder: 1 heaping tablespoonful (2 g methylcellulose per 19 g powder) in at least 240 ml (8 oz) of water PO, given 1 to 3 times per day as needed	Caplet: 12 caplets/day Powder: 6 grams/day
sennosides (Senokot [®])	1 to 2 tablets (8.6 to 17.2 mg sennosides) PO BID	68.8 mg sennosides/day

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
bisacodyl (Dulcolax [®])	5 to 15 mg/day (1 to 3 tablets) PO given as a single dose, or 1 suppository or retention enema (10 mg) PR QD Either a suppository or oral tablet(s) may be used up to 3 times per week	15 mg/day PO or 10 mg/day PR
polyethylene glycol 3350 (MiraLax [®])	17 g (approximately 1 heaping tablespoon) of powder in 120 to 240 mL of fluid PO QD	34 grams/day
lubiprostone (Amitiza [®])	IBS-C: 8 mcg PO BID CIC: 24 mcg PO BID	IBS-C: 16 mcg/day CIC: 48 mcg/day
Linzess [®] (linaclotide)	IBS-C: 290 mcg PO QD CIC: 72 mcg or 145 mcg PO QD	IBS-C: 290 mcg/day CIC: 145 mcg/day

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): patients less than 6 years of age due to the risk of serious dehydration, patients with known or suspected mechanical gastrointestinal obstruction
- Boxed warning(s): risk of serious dehydration in pediatric patients

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CIC, IBS-C	3 mg PO QD	3 mg/day

VI. Product Availability

Tablet: 3 mg

VII. References

1. Trulance Prescribing Information. New York, NY: Synergy Pharmaceuticals Inc.; March 2024. Available at: www.trulance.com. Accessed July 12, 2024.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2020. Available at: <http://www.clinicalpharmacology-ip.com/>. Accessed August 1, 2024.

Chronic Idiopathic Constipation

3. Bharucha AE, Pemberton JH, Locke GR. American Gastroenterological Association technical review on constipation. *Gastroenterol.* 2013;144(1):218-38.
4. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. *Am J Gastroenterol.* 2014;109 Suppl 1:S2-26.
5. Koliani-pace J, Lacy BE. Update on the Management of Chronic Constipation. *Curr Treat Options Gastroenterol.* 2017.

6. Miner PB, Koltun WD, Wiener GJ, et al. A randomized Phase III clinical trial of plecanatide, an uroguanylin analog, in patients with chronic idiopathic constipation. *Am J Gastroenterol*. February 2017. doi:10.1038/ajg.2016.611.
 7. Hayat U, Dugum M, Garg S. Chronic constipation: update on management. *Cleveland Clinic Journal of Medicine*. 2017 May;84(5):397-408.
 8. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. Dioctyl sulfosuccinate or docusate (calcium or sodium) for the prevention or management of constipation: a review of the clinical effectiveness. www.ncbi.nlm.nih.gov/pubmedhealth/PMH0071207/. Accessed July 11, 2023
 9. Paquette IM, Varma M, Ternent C, et al. The American Society of Colon and Rectal Surgeons' Clinical Practice Guideline for the Evaluation and Management of Constipation. *Dis Colon Rectum*. 2016;59:479-492.
 10. American Gastroenterological Association, Bharucha AE, Dorn SD et al. American Gastroenterological Association medical position statement on constipation. *Gastroenterol*. 2013;144(1):211-7. doi: 10.1053/j.gastro.2012.10.029.
 11. Lin C, Chey WD, Imdad A, et al. American Gastroenterological Association-American College of Gastroenterology clinical practice guideline: Pharmacological management of chronic idiopathic constipation. *Gastroenterology* 2023;164:1086-1106.
- Irritable Bowel Syndrome with Constipation*
12. Weinberg DS, Smalley W, Heidelbaugh JJ, Shahnaz S. American Gastroenterological Association Institute guideline on the pharmacological management of irritable bowel syndrome. *Gastroenterology*. 2014; 147(5): 1146-1149. Available at: [https://www.gastrojournal.org/article/S0016-5085\(14\)01089-0/pdf](https://www.gastrojournal.org/article/S0016-5085(14)01089-0/pdf).
 13. Lacy BE, Pimentel M, Brenner DM. ACG clinical guideline: Management of irritable bowel syndrome. *American Journal of Gastroenterology*. 2021; 116(1): 17-44.
 14. Chang L, Sultan S, Lembo A, et al. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. *Gastroenterology*. 2022;163:118-136.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2020 annual review: added HIM line of business; references reviewed and updated.	06.29.20	11.20
Removed HIM line of business per March SDC.	03.26.21	05.21
4Q 2021 annual review: no significant changes; legacy WCG Medicaid to apply (WCG.CP.PMN.87 to be retired); references reviewed and updated.	08.12.21	11.21
4Q 2022 annual review: no significant changes; references reviewed and updated. Template changes applied to other diagnoses/indications and continued therapy section.	07.26.22	11.22
4Q 2023 annual review: no significant changes; references reviewed and updated.	07.05.23	11.23
Per December SDC, added HIM line of business (retire HIM.PA.158); added redirection to generic lubiprostone and Linzess.	12.06.23	02.24

Reviews, Revisions, and Approvals	Date	P&T Approval Date
4Q 2024 annual review: no significant changes; references reviewed and updated.	07.12.24	11.24
Per December SDC, removed HIM line of business as PA is no longer required.	12.02.24	02.25

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.